{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Risperdal+%28risperidone%29+Consta", "query": { "intervention": "Risperdal (risperidone) Consta" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 23, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Risperdal+%28risperidone%29+Consta&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-27T22:19:21.936Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00330551", "title": "Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "Oral Risperidone", "type": "DRUG" }, { "name": "Risperidone in Long-Acting Injectable Form (Consta)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, Los Angeles", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 126, "start_date": "2006-03", "completion_date": "2012-11", "has_results": true, "last_update_posted_date": "2023-03-01", "last_synced_at": "2026-09-27T22:19:21.936Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00330551" }, { "nct_id": "NCT00845572", "title": "The Consta Club: A Demonstration Project for Setting up a Consta Club in a Community Mental Health Center", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Schizophrenia", "Schizoaffective" ], "interventions": [ { "name": "Consta Club", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "The University of Texas Health Science Center at San Antonio", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 30, "start_date": "2007-01", "completion_date": "2010-06", "has_results": false, "last_update_posted_date": "2012-09-18", "last_synced_at": "2026-09-27T22:19:21.936Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00845572" }, { "nct_id": "NCT00330863", "title": "Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Schizophrenia", "Schizoaffective Disorder" ], "interventions": [ { "name": "Risperidone microspheres", "type": "DRUG" }, { "name": "Risperidone", "type": "DRUG" }, { "name": "Olanzapine", "type": "DRUG" }, { "name": "Quetiapine", "type": "DRUG" }, { "name": "Ziprasidone", "type": "DRUG" }, { "name": "Aripiprazole", "type": "DRUG" }, { "name": "Paliperidone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Northwell Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 357, "start_date": "2006-05", "completion_date": "2011-01", "has_results": true, "last_update_posted_date": "2018-07-10", "last_synced_at": "2026-09-27T22:19:21.936Z", "location_count": 8, "location_summary": "Los Angeles, California • Augusta, Georgia • Iowa City, Iowa + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Fall River", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00330863" }, { "nct_id": "NCT02411526", "title": "Safety and PK Trial With Injectable ZX003 (Risperidone-SABER®) Compared to Risperdal® Consta® in Stable Schizophrenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Schizophrenia", "Schizoaffective Disorder" ], "interventions": [ { "name": "ZX003 (Risperidone-SABER®)", "type": "DRUG" }, { "name": "Risperdal Consta", "type": "DRUG" }, { "name": "Oral Risperidone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Zogenix, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 60, "start_date": "2015-02", "completion_date": "2015-09", "has_results": false, "last_update_posted_date": "2022-10-31", "last_synced_at": "2026-09-27T22:19:21.936Z", "location_count": 1, "location_summary": "Long Beach, California", "locations": [ { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02411526" }, { "nct_id": "NCT00314613", "title": "Functional Brain Imaging and Employment in First-Episode Psychotic Patients Treated With Risperdal", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "Antipsychotic/Risperidone Consta", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "18 Years to 40 Years" }, "enrollment_count": 30, "start_date": "2006-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2017-12-02", "last_synced_at": "2026-09-27T22:19:21.936Z", "location_count": 2, "location_summary": "Butner, North Carolina • Durham, North Carolina", "locations": [ { "city": "Butner", "state": "North Carolina" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00314613" }, { "nct_id": "NCT02186769", "title": "An Randomized Open-Label PK Study of LY03004 Compared to Risperdal® Consta® in Stable Patients With Schizophrenia or Schizoaffective Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Schizophrenia", "Schizoaffective Disorder" ], "interventions": [ { "name": "Risperdal® Consta®", "type": "DRUG" }, { "name": "LY03004", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Luye Pharma Group Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 16, "start_date": "2014-07", "completion_date": "2015-04", "has_results": false, "last_update_posted_date": "2015-06-18", "last_synced_at": "2026-09-27T22:19:21.936Z", "location_count": 2, "location_summary": "Orange County, California • Austin, Texas", "locations": [ { "city": "Orange County", "state": "California" }, { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02186769" }, { "nct_id": "NCT00246194", "title": "Observational Study in Patients With Schizophrenia Treated With Long-Acting Risperidone Injection (RISPERDAL CONSTA)", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "risperidone (RISPERDAL CONSTA)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen, LP", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 532, "start_date": "2004-09", "completion_date": "2007-11", "has_results": false, "last_update_posted_date": "2014-04-04", "last_synced_at": "2026-09-27T22:19:21.936Z", "location_count": 1, "location_summary": "Rockville, Maryland", "locations": [ { "city": "Rockville", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00246194" }, { "nct_id": "NCT00215579", "title": "Determining the Effects of Risperdal Consta in Patients With Psychotic Disorders and Incomplete Adherence", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Schizophrenia", "Schizoaffective Disorder" ], "interventions": [ { "name": "Depot Risperidone Microsphere (Consta)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 64, "start_date": "2004-04", "completion_date": "2006-04", "has_results": false, "last_update_posted_date": "2014-09-22", "last_synced_at": "2026-09-27T22:19:21.936Z", "location_count": 1, "location_summary": "Butner, North Carolina", "locations": [ { "city": "Butner", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00215579" }, { "nct_id": "NCT00333177", "title": "Psychosocial Therapy and Risperidone Treatment in Work Performance in Recent-Onset Schizophrenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "Cognitive remediation training (CT)", "type": "BEHAVIORAL" }, { "name": "Healthy behavior training (HBT)", "type": "BEHAVIORAL" }, { "name": "Risperidone, administered orally (Oral Ris)", "type": "DRUG" }, { "name": "Risperidone, administered via injection (RLAI)", "type": "DRUG" } ], "intervention_types": [ "BEHAVIORAL", "DRUG" ], "sponsor": "University of California, Los Angeles", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 92, "start_date": "2006-03", "completion_date": "2013-01", "has_results": true, "last_update_posted_date": "2020-03-26", "last_synced_at": "2026-09-27T22:19:21.936Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00333177" }, { "nct_id": "NCT00313391", "title": "Risperdal Consta and Health Care Utilization in Patients With Schizophrenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Schizophrenia", "Schizoaffective Disorder" ], "interventions": [ { "name": "Risperdal Consta", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": null, "start_date": "2005-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-09-25", "last_synced_at": "2026-09-27T22:19:21.936Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00313391" } ] }